HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

glycyltyrosine (Gly-Tyr)

Also Known As:

Gly-Tyr; glycyl-L-tyrosine; glycyl-tyrosine; N-glycyl-L-tyrosine

Networked: 12 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - glycyltyrosine: 12

Experts

1.	Cai, Yuan: 1 article (01/2022)
2.	Gao, Caixia: 1 article (01/2022)
3.	Jiao, Ting: 1 article (01/2022)
4.	Li, Yongqing: 1 article (01/2022)
5.	Liu, Xuanbo: 1 article (01/2022)
6.	Ren, Yue: 1 article (01/2022)
7.	Wang, Zhengwen: 1 article (01/2022)
8.	Yang, Yanan: 1 article (01/2022)
9.	Yuan, Haonan: 1 article (01/2022)
10.	Zhao, Shengguo: 1 article (01/2022)

Related Diseases

1.	Amyloid Plaque 11/01/1987 - "The N-terminal sequence was: Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr, which is identical to the N-terminal sequence of the 4,200-dalton peptide isolated previously from extraparenchymal meningeal vessels and neuritic plaques.(ABSTRACT TRUNCATED AT 250 WORDS)" 12/01/1985 - "A synthetic peptide (Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr), homologous to the amino terminus of a protein purified from cerebrovascular amyloid (beta protein), induced antibodies in BALB/c mice that were used immunohistochemically to stain not only amyloid-laden cerebral vessels but neuritic plaques as well. "
2.	Liver Failure 04/01/1995 - "In hepatic failure, elimination and hydrolysis of Ala-Tyr and Gly-Tyr were comparable to controls, but Cltot of Nac-Tyr was reduced (236 +/- 26 mL/kg/min). " 04/01/1995 - "The ratio of glycine to tyrosine (Gly/Tyr) was 16.7 +/- 4.85 in the myeloma group and 1.7 +/- 0.12 in the liver failure group. " 04/01/1995 - "The impact of hepatic dysfunction on the elimination and hydrolysis of three potential tyrosine sources for total parenteral nutrition, the dipeptides L-alanyl-L-tyrosine (Ala-Tyr) and glycyl-L-tyrosine (Gly-Tyr), and N-acetyl-L-tyrosine (Nac-Tyr) were evaluated in six patients with hepatic failure (five chronic, one acute) and seven healthy subjects. "
3.	Body Weight (Weight, Body) 03/01/1996 - "We investigated the use of a highly soluble synthetic dipeptide, glycyl-L-tyrosine, as a parenteral tyrosine source in 18 male Wistar rats (body weight 180-200 g). " 11/01/1978 - "Experiments on male rats showed that following subcutaneous injection of alloxan in a dose of 15 mg per 100 g of body weight amylolytic, invertase, glycyl-l-tyrosine dipeptidehydrolase activity of the mucosa of the small intestine altered differently. "
4.	Acute Kidney Injury (Acute Renal Failure) 10/01/1997 - "The plasma concentration of glycyl-tyrosine was at the limit of detectability indicating rapid hydrolysis of the dipeptide in acute renal failure. " 10/01/1997 - "Influence of a novel amino acid solution (enriched with the dipeptide glycyl-tyrosine) on plasma amino acid concentration of patients with acute renal failure."
5.	Renal Insufficiency (Renal Failure) 02/01/1991 - "Thus renal failure does not impair Ala-Tyr disposal and delays Gly-Tyr utilization. " 02/01/1991 - "The impact of renal failure on the elimination and hydrolysis of three sources of tyrosine for parenteral nutrition, the dipeptides alanyltyrosine (Ala-Tyr), glycyltyrosine (Gly-Tyr), and N-acetyltyrosine (NAc-Tyr) was investigated in eight patients on regular hemodialysis therapy (HD) and seven healthy controls (CON). "

Related Drugs and Biologics

1.	Tyrosine (L-Tyrosine)
2.	Dipeptides
3.	glycyltyrosine (Gly-Tyr)
4.	Peptides (Polypeptides)
5.	N-acetyltyrosine
6.	Solutions
7.	phenylalanylarginine
8.	alanylglutamic acid
9.	alanyltyrosine
10.	beta-Fructofuranosidase (Invertase)

Related Therapies and Procedures

1.	Therapeutics
2.	Total Parenteral Nutrition
3.	Parenteral Nutrition
4.	Subcutaneous Injections
5.	Renal Dialysis (Hemodialysis)